Characteristics of transplant recipients and donors
| Variable/characteristic . | No. of cases (%) . |
|---|---|
| Age, y | |
| Median: 50 | |
| Range: 17-75 | |
| Sex | |
| Recipient | |
| Male | 240 (58.0) |
| Female | 174 (42.0) |
| Donor | |
| Male | 252 (60.9) |
| Female | 162 (39.1) |
| Recipient/donor | |
| Male/male | 151 (36.5) |
| Male/female | 90 (21.7) |
| Female/male | 100 (24.2) |
| Female/female | 73 (17.6) |
| Diagnosis | |
| AML | 178 (43.0) |
| ALL | 65 (15.7) |
| CML | 22 (5.3) |
| CLL | 15 (3.6) |
| MDS | 42 (10.1) |
| HL | 12 (2.9) |
| NHL | 43 (10.4) |
| MM | 25 (6.0) |
| MF | 5 (1.2) |
| AA | 4 (1.0) |
| PNH | 3 (0.7) |
| Donor | |
| Sibling | 245 (59.2) |
| mud/mm | 169 (40.8) |
| Conditioning regimen | |
| Classical myeloablative | 130 (31.4) |
| Reduced-intensity conditioning | 124 (29.9) |
| Reduced-toxicity myeloablative | 86 (17.9) |
| Fludarabine/melphalan | 74 (20.8) |
| Variable/characteristic . | No. of cases (%) . |
|---|---|
| Age, y | |
| Median: 50 | |
| Range: 17-75 | |
| Sex | |
| Recipient | |
| Male | 240 (58.0) |
| Female | 174 (42.0) |
| Donor | |
| Male | 252 (60.9) |
| Female | 162 (39.1) |
| Recipient/donor | |
| Male/male | 151 (36.5) |
| Male/female | 90 (21.7) |
| Female/male | 100 (24.2) |
| Female/female | 73 (17.6) |
| Diagnosis | |
| AML | 178 (43.0) |
| ALL | 65 (15.7) |
| CML | 22 (5.3) |
| CLL | 15 (3.6) |
| MDS | 42 (10.1) |
| HL | 12 (2.9) |
| NHL | 43 (10.4) |
| MM | 25 (6.0) |
| MF | 5 (1.2) |
| AA | 4 (1.0) |
| PNH | 3 (0.7) |
| Donor | |
| Sibling | 245 (59.2) |
| mud/mm | 169 (40.8) |
| Conditioning regimen | |
| Classical myeloablative | 130 (31.4) |
| Reduced-intensity conditioning | 124 (29.9) |
| Reduced-toxicity myeloablative | 86 (17.9) |
| Fludarabine/melphalan | 74 (20.8) |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; AA, aplastic anemia; classical myeloablative, Cy/TBI (high-dose cyclophosphamide and total body irradiation) and ivBuCy (high-dose intravenous busulfan and cyclophosphamide); CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; mud/mm, matched unrelated or mismatched unrelated donor; NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; reduced-intensity conditioning, fludarabine with reduced doses of busulfan; reduced-toxicity myeloablative, fludarabine with high-dose busulfan or treosulfan.